mesalamine has been researched along with pulmicort in 134 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (11.94) | 18.2507 |
| 2000's | 42 (31.34) | 29.6817 |
| 2010's | 66 (49.25) | 24.3611 |
| 2020's | 10 (7.46) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andus, T; Gross, V; Schölmerich, J | 1 |
| Irvine, EJ; Marshall, JK | 1 |
| Ekström, GM | 1 |
| Rutgeerts, P; Vermeire, S | 1 |
| Tytgat, GN; van Deventer, SJ | 1 |
| Breslin, NP; Sutherland, LR | 1 |
| Cortot, A; Jewell, D; Persson, T; Pettersson, E; Thomsen, OO; Vatn, M; Veloso, FT; Winter, T; Wright, JP | 2 |
| Bickston, SJ; Cominelli, F | 1 |
| Klotz, U | 1 |
| Stange, EF | 2 |
| Lowry, PW; Sandborn, WJ | 1 |
| Hüppe, D; Schenck, B; Tromm, A | 1 |
| Rutgeerts, P | 1 |
| Hellström, PM; Ljung, T; Martinsson, T; Rubio, C | 1 |
| Takada, K | 1 |
| Frühmorgen, P; Huber, W; Kimmig, JM; Rufle, W | 1 |
| Rachmilewitz, D | 1 |
| de Groot, H; de Man, RA; Heeringa, M; Zweers, P | 1 |
| Sutherland, LR | 1 |
| Fleig, WE | 2 |
| Evans, DF; Kumar, D; Nugent, SG; Rampton, DS | 1 |
| Rutgeerts, PJ | 1 |
| Adler, G; König, HH; Leidl, R; Reinshagen, M; Rösch, M; Thomas, S; von Tirpitz, C | 1 |
| Farthing, MJ | 1 |
| Niemelä, S | 1 |
| Feagan, BG; Hofer, T; Kane, SV; Sandborn, WJ; Schoenfeld, P; Tremaine, W | 1 |
| Cohen, RD | 1 |
| Feagan, BG; Sandborn, WJ | 2 |
| Castro Fernández, M; Galán Jurado, V; García Díaz, E; Rodríguez Alonso, C; Romero, M | 1 |
| Schölmerich, J | 1 |
| Espinós, J; Esteve, M; Fernández-Bañares, F; Forné, M; Salas, A; Viver, JM | 1 |
| Kullak-Ublick, GA; Rammert, Ch | 1 |
| Beglinger, Ch | 1 |
| Calabrese, E; Cammà, C; Casà, A; Cottone, M; Orlando, A; Viscido, A | 1 |
| Archavlis, E; Chadio-Iordanides, H; Christidou, A; Mantzaris, GJ; Petraki, K; Sfakianakis, M; Triadaphyllou, G | 1 |
| Dressman, J; Klein, S; Stein, J | 1 |
| Munck, LK | 1 |
| Büning, C; Lochs, H | 1 |
| Gottesleben, F | 1 |
| Lakatos, L; Lakatos, PL | 1 |
| Thomson, A | 1 |
| de Castro Losa, MR; de la Iglesia Fanjul, I; Izquierdo García, F | 1 |
| Detsky, A; Kennedy, ED; Llewellyn-Thomas, HA; McLeod, RS; Steinhart, AH; To, T | 1 |
| Chande, N; Macdonald, JK; McDonald, JW | 2 |
| Bakulin, IG; Stanke, DA | 1 |
| Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP | 1 |
| Bischoff, A | 1 |
| Ahmadi, F; Dorkoosh, F; Emami, J; Fassihi, A; Mahzouni, P; Minaiyan, M; Tavakoli, N; Varshosaz, J | 1 |
| Hartmann, F; Stein, J | 1 |
| Bourke, B; Cortelazzo, S; Piccin, A; Rovigatti, U; Smith, OP | 1 |
| Dennis, M; Jamma, S; Kelly, CP; Leffler, DA; Najarian, RM; Schuppan, DB; Sheth, S | 1 |
| Griffiths, AM; Seow, CH; Sherlock, ME; Steinhart, AH | 1 |
| Altorjay, I; Bar-Meir, S; Bátovský, M; Bunganič, I; Dilger, K; Fixa, B; Gabalec, L; Glasmacher, C; Greinwald, R; Koutroubakis, I; Kramm, HJ; Kykal, J; Löhr, H; Lukáš, M; Mohrbacher, R; Safadi, R; Schäffeler, E; Stimac, D; Tomsová, E; Tromm, A; Tulassay, Z | 1 |
| Hanauer, S; Lim, WC | 1 |
| Belousova, EA; Bunganic, I; Derova, J; Dilger, K; Dorofeyev, AE; Gabalec, L; Greinwald, R; Gross, V; Kiudelis, G; Kupcinskas, L; Mikhailova, TL; Mueller, R; Tulassay, Z | 1 |
| Blumenstein, I; Bock, H; Dignass, A; Filmann, N; Hartmann, F; Herrmann, E; Schröder, O; Stein, J; Tacke, W; Zeuzem, S; Zosel, C | 1 |
| Blonski, W; Buchner, AM; Lichtenstein, GR | 1 |
| Danese, S; Fiorino, G; Montorsi, M; Sacchi, M; Spinelli, A | 1 |
| Bousvaros, A; Carvalho, R; Evans, J; Griffiths, A; Grossman, A; Hyams, J; Kay, M; Keljo, D; Langton, C; LeLeiko, N; Lerer, T; Mack, D; Markowitz, J; Oliva-Hemker, M; Otley, A; Pfefferkorn, M; Rosh, J; Samson, C; Stephens, M | 1 |
| Cheon, JH; Choi, CH; Jang, BI; Kim, YH; Lee, H; Lee, KM; Shin, SJ; Yang, SK; Ye, BD | 1 |
| Ascolani, M; Biancone, L; Boirivant, M; Cossu, A; Pallone, F | 1 |
| Bagin, R; Ballard, ED; Gautille, T; Huang, M; Jones, R; Moro, L; Sandborn, WJ; Travis, S; Yeung, P | 1 |
| Wenzl, HH | 1 |
| Biedermann, L; Frei, P; Manser, CN; Manz, M; Rogler, G; Vavricka, SR; Wilk, M | 1 |
| Gross, V | 1 |
| Erichsen, Jv; Hessmann, M; Hoffmeyer, A; Pahl, A; Sann, H | 1 |
| D'Haens, GR; Rietdijk, ST | 1 |
| Beglinger, C; Fournier, N; Mottet, C; Pittet, V; Rogler, G; Seibold, F | 1 |
| Aratari, A; Clemente, V; De Gregorio, AM; Fascì Spurio, F; Koch, M; Margagnoni, G; Papi, C; Spagnolo, A | 1 |
| Bach, H; Bressler, B; Grist, J; Silverberg, MS; Stempak, JM; Xia, A | 1 |
| Böhm, G; Bonderup, OK; Fernández-Bañares, F; Greinwald, R; Kupcinskas, L; Madisch, A; Marks, HJ; Miehlke, S; Mohrbacher, R; Nathan, T; Neumeyer, M; Petrauskas, D; Vieth, M | 1 |
| Rogler, G; Scharl, M; Schoepfer, AM; Vavricka, SR | 1 |
| Danese, S; Peyrin-Biroulet, L; Siegel, CA | 1 |
| Antoniu, SA; Drug, VL | 1 |
| Bagin, R; D'Haens, G; Danese, S; David Ballard, E; Huang, M; Jones, R; Masure, J; Moro, L; Sandborn, WJ; Travis, S | 1 |
| Bonovas, S; Danese, S; Del Giovane, C; Fiorino, G; Moja, L | 1 |
| Benchimol, EI; Griffiths, AM; Kaplan, GG; Kuenzig, ME; Otley, AR; Rezaie, A; Seow, CH; Steinhart, AH | 1 |
| Geboes, K; Jauregui-Amezaga, A; Vermeire, S | 1 |
| Griffiths, AM; MacDonald, JK; Seow, CH; Sherlock, ME; Steinhart, AH | 1 |
| Chande, N; Feagan, BG; Marshall, JK; Nelson, S; Parker, CE; Sandborn, WJ; Seow, CH | 1 |
| Bohr, J; Bonderup, OK; Greinwald, R; Madisch, A; Miehlke, S; Mohrbacher, R; Mueller, R; Münch, A; Ström, M; Tysk, C | 1 |
| Stiefelhagen, P | 1 |
| Eissens, AC; Frijlink, HW; Gareb, B; Kosterink, JGW | 1 |
| Abdalla, MI; Herfarth, H | 1 |
| Hanauer, S; Lim, WC; MacDonald, JK; Wang, Y | 1 |
| Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ | 1 |
| Andrade, P; Gomes, S; Macedo, G; Nunes, AC; Silva, M | 1 |
| Bezzio, C; Fascì-Spurio, F; Meucci, G; Papi, C; Saibeni, S; Viganò, C | 1 |
| Pardi, DS | 1 |
| Im, JP; Kim, JW; Lee, H; Lee, KM; Park, DI; Park, JJ; Yang, SK; Ye, BD; Yoon, H; Yoon, SN | 1 |
| Clement, F; Coward, S; Ghosh, S; Hazlewood, G; Holmes, R; Kaplan, GG; Kuenzig, ME; McBrien, K; Panaccione, R; Rezaie, A; Seow, CH | 1 |
| Bonovas, S; Danese, S; Peyrin-Biroulet, L | 2 |
| Axler, J; Barrett, AC; Bortey, E; Cohen, RD; Forbes, WP; Lichtenstein, GR; Riddell, RH; Rubin, DT; Sandborn, WJ; Zhu, C | 1 |
| Al Yatama, N; Bhanji, T; Chande, N; MacDonald, JK; McDonald, JW; Nguyen, TM | 1 |
| Chande, N; Kafil, TS; MacDonald, JK; McDonald, JW; Nguyen, TM; Patton, PH | 1 |
| Bezzio, C; Festa, S; Manes, G; Papi, C; Saibeni, S; Zerboni, G | 1 |
| Abdulkhakov, S; Alekseeva, O; Andreev, P; Datsenko, O; Dorofeyev, AE; Greinwald, R; Kruis, W; Levchenko, O; Lozynskyy, Y; Mohrbacher, R; Mostovoy, Y; Neshta, V; Pesegova, M; Siegmund, B; Soloviev, K; Stiess, M; Vieth, M | 1 |
| Dulai, PS; Fumery, M; Murad, MH; Nguyen, NH; Prokop, LJ; Sandborn, WJ; Singh, S | 1 |
| Armerding, P; Aust, D; Böhm, G; Bonderup, O; Fernández-Bañares, F; Greinwald, R; Kupcinskas, J; Miehlke, S; Mihaly, E; Münch, A; Munck, LK; Nacak, T; Rehbehn, KU | 1 |
| Barańska-Rybak, W; Mehrholz, D; Nowak, M; Nowicki, J | 1 |
| Ananthakrishnan, AN; Long, MD; Rubin, DT; Sauer, BG; Siegel, CA | 1 |
| Afif, W; Bernstein, CN; Bitton, A; Borgaonkar, M; Bressler, B; Chauhan, U; Halloran, B; Jones, J; Kennedy, E; Khanna, R; Leontiadis, GI; Loftus, EV; Marshall, JK; Meddings, J; Moayyedi, P; Murthy, S; Panaccione, R; Plamondon, S; Rosenfeld, G; Schwartz, D; Seow, CH; Steinhart, AH; Targownik, L; Williams, C | 1 |
| Kang, SB; Lee, J; Park, M; Park, Y | 1 |
| Bonovas, S; Danese, S; González-Lorenzo, M; Lytras, T; Nikolopoulos, GK; Pantavou, K; Peyrin-Biroulet, L; Piovani, D | 1 |
| Ardizzone, S; Bezzio, C; Bosani, M; Carmagnola, S; Cassinotti, A; Chibbar, R; Dell'Era, A; Grillo, S; Landi, S; Maconi, G; Massari, A; Mezzina, N; Molteni, P; Pastorelli, L | 1 |
| Bonovas, S; D'Haens, G; Danese, S; Dignass, A; Dotan, I; Fiorino, G; Hart, A; Louis, E; Paridaens, K; Peyrin-Biroulet, L; Rogler, G | 1 |
| Casanova, MJ; Gisbert, JP; Rojo, E | 1 |
| Brandimarte, G; Cassieri, C; Colucci, R; Elisei, W; Picchio, M; Tursi, A | 1 |
| Armentano, R; Cavalcanti, E; Lolli, I | 1 |
| Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S | 1 |
| Kaliaperumal, S; Sahoo, NK; Senthamizh, T; Senthamizhselvan, K | 1 |
| Atmakuri, S; Hoque, S; Khatri, D; Kumar, R; Madan, J; Mahajan, S; Maji, I; Modani, S; Singh, PK; Sriram, A; Srivastava, S; Tangirala, S | 1 |
| Abdulkhakov, S; Abrahamovych, O; Alexeeva, O; Andreev, P; Baluta, M; Datsenko, O; Delmans, G; Dorofeyev, A; Greinwald, R; Kharchenko, N; Khimion, L; Kolesnik, IP; Kruis, W; Lesniakowski, K; Levchenko, O; Maksyashina, SV; Mihaly, E; Mohrbacher, R; Mostovoy, Y; Mueller, R; Pokrotnieks, J; Sablin, OA; Siegmund, B; Simanenkov, V; Sobon, M; Uspenskiy, Y; Viacheslav, N; Vieth, M | 1 |
| Akita, Y; Iwashita, Y; Maruyama, Y; Miyashita, H; Miyazaki, R; Sakurai, T; Saruta, M; Shibuya, N; Shimada, M | 1 |
| Caron, B; D'Amico, F; Danese, S; Jairath, V; Magro, F; Paridaens, K; Peyrin-Biroulet, L | 1 |
| Aruljothy, A; Caron, B; Danese, S; Hogan, M; Jairath, V; Ma, C; MacDonald, JK; Moran, GW; Narula, N; Peyrin Biroulet, L; Singh, S; Vuyyuru, SK; Zayadi, A | 1 |
60 review(s) available for mesalamine and pulmicort
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Crohn disease: prevention and drug therapy].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Immunosuppressive Agents; Mesalamine; Pregnenediones; Recurrence | 1995 |
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Glucocorticoids; Humans; Mesalamine; Pregnenediones; Randomized Controlled Trials as Topic; Suppositories | 1997 |
[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
Topics: Anti-Inflammatory Agents; Budesonide; Colon; Crohn Disease; Follow-Up Studies; Humans; Ileum; Mesalamine; Metronidazole; Postoperative Complications; Recurrence | 1998 |
[Drug treatment of Crohn's disease].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical Protocols; Crohn Disease; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mesalamine; Methotrexate; Prednisone; Remission Induction; Treatment Outcome | 1998 |
The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Digestive System Surgical Procedures; Humans; Mesalamine; Metronidazole; Postoperative Period; Prognosis; Randomized Controlled Trials as Topic; Secondary Prevention | 1998 |
[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
Topics: Budesonide; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Mesalamine; Structure-Activity Relationship | 1999 |
[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Clinical Trials as Topic; Crohn Disease; Drug Delivery Systems; Humans; Mesalamine; Treatment Outcome | 1999 |
[DDS preparations of drugs for inflammatory bowel disease].
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Capsules; Delayed-Action Preparations; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mesalamine; Prednisolone; Prodrugs | 1999 |
[New therapeutic modalities in Crohn's disease].
Topics: Anti-Inflammatory Agents; Budesonide; Crohn Disease; Humans; Mesalamine; Prednisolone | 1999 |
Prevention of relapse of Crohn's disease.
Topics: Budesonide; Crohn Disease; Gastrointestinal Agents; Humans; Mesalamine; Secondary Prevention | 2000 |
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases].
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Mesalamine; Recurrence | 2001 |
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biological Availability; Budesonide; Catheterization; Electrodes; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Reference Values; Telemetry | 2001 |
Conventional treatment of Crohn's disease: objectives and outcomes.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Mesalamine; Methotrexate; Prednisone; Quality of Life; Recurrence; Sulfasalazine; Treatment Outcome | 2001 |
[Drug therapy of Crohn disease].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Crohn Disease; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Secondary Prevention; Treatment Outcome | 2001 |
The effectiveness of budesonide therapy for Crohn's disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction | 2002 |
Evolving medical therapies for ulcerative colitis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antineoplastic Agents; Budesonide; Colitis, Ulcerative; Cyclosporine; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Interferons; Mesalamine; Treatment Outcome | 2002 |
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2002 |
[Management of ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antiviral Agents; Azathioprine; Budesonide; Clinical Trials as Topic; Colectomy; Colitis, Ulcerative; Colonic Pouches; Colonoscopy; Colorectal Neoplasms; Cyclosporins; Gastrointestinal Agents; Humans; Hydrocortisone; Immunosuppressive Agents; Infliximab; Injections, Intravenous; Interferons; Mercaptopurine; Mesalamine; Osteoporosis; Placebos; Practice Guidelines as Topic; Recurrence; Remission Induction; Risk Factors; Suppositories; Time Factors | 2003 |
[Treatment of Crohn's disease].
Topics: Acute Disease; Adjuvants, Immunologic; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Case-Control Studies; Clinical Trials as Topic; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Metronidazole; Osteoporosis; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Review article: prevention of postsurgical relapse and recurrence in Crohn's disease.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Immunosuppressive Agents; Mesalamine; Metronidazole; Ornidazole; Probiotics; Risk Factors; Secondary Prevention; Smoking | 2003 |
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Topics: Administration, Topical; Algorithms; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Controlled Clinical Trials as Topic; Crohn Disease; Gastrointestinal Agents; Glucocorticoids; Humans; Mesalamine; Sulfasalazine | 2003 |
Conventional therapy for Crohn's disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Nutrition Therapy; Randomized Controlled Trials as Topic; Remission Induction | 2006 |
[Medical therapy of inflammatory bowel diseases: Crohn's disease].
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Chronic Disease; Crohn Disease; Fistula; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Mesalamine; Methotrexate; Severity of Illness Index | 2007 |
Interventions for treating lymphocytic colitis.
Topics: Antidiarrheals; Bismuth; Budesonide; Cholestyramine Resin; Colitis, Lymphocytic; Humans; Mesalamine; Organometallic Compounds; Randomized Controlled Trials as Topic; Salicylates | 2008 |
Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Cholestyramine Resin; Colitis, Microscopic; Humans; Mesalamine; Probiotics; Randomized Controlled Trials as Topic; Salicylates | 2009 |
[Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Budesonide; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Prednisolone | 2008 |
[For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Child; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Enteral Nutrition; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Mesalamine; Meta-Analysis as Topic; Middle Aged; Prednisone; Pregnancy; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
Oral budesonide for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction | 2010 |
Aminosalicylates for induction of remission or response in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction; Sulfasalazine | 2010 |
Update on the management of Crohn's disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Budesonide; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Mesalamine; Methotrexate; Natalizumab; Sulfasalazine; Tumor Necrosis Factor-alpha | 2011 |
Risk of postoperative recurrence and postoperative management of Crohn's disease.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Crohn Disease; Endoscopy; Gastroenterology; Humans; Inflammation; Mesalamine; Postoperative Period; Recurrence; Risk; Risk Factors; Treatment Outcome | 2011 |
Diarrhea in chronic inflammatory bowel diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Bacterial Infections; Biopsy; Bismuth; Blood Cell Count; Blood Chemical Analysis; Body Water; Breath Tests; Budesonide; Cholestyramine Resin; Colitis, Microscopic; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Feces; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Absorption; Intestinal Fistula; Intestinal Mucosa; Intestines; Ion Transport; Malabsorption Syndromes; Medical History Taking; Mesalamine; Organometallic Compounds; Physical Examination; Postoperative Complications; Prednisolone; Salicylates; Sodium; Tumor Necrosis Factor-alpha | 2012 |
Topical therapies in inflammatory bowel disease.
Topics: Administration, Rectal; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Drug Therapy, Combination; Enema; Guideline Adherence; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Patient Compliance; Practice Guidelines as Topic; Suppositories | 2012 |
Topical therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Rectum | 2012 |
Recent developments in the treatment of inflammatory bowel disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Budesonide; Certolizumab Pegol; Evidence-Based Practice; Humans; Immunoglobulin Fab Fragments; Inflammatory Bowel Diseases; Mesalamine; Polyethylene Glycols; Rifamycins; Rifaximin; Ustekinumab | 2013 |
[Prevention of post-operative recurrence in Crohn's disease: a critical review of randomized controlled trials and meta-analyses of different therapeutic strategies].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Budesonide; Combined Modality Therapy; Crohn Disease; Drug Therapy, Combination; Endoscopy, Digestive System; Humans; Immunosuppressive Agents; Infliximab; Interleukin-10; Lactobacillus; Mesalamine; Meta-Analysis as Topic; Multicenter Studies as Topic; Probiotics; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2013 |
Steroid use in Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; Mercaptopurine; Mesalamine; Tumor Necrosis Factor-alpha | 2014 |
Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
Topics: Algorithms; Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Colitis, Ulcerative; Delayed-Action Preparations; Glucocorticoids; Humans; Mesalamine; Severity of Illness Index | 2014 |
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Topics: Adult; Bayes Theorem; Budesonide; Crohn Disease; Humans; Mesalamine; Odds Ratio; Randomized Controlled Trials as Topic | 2015 |
Budesonide for induction of remission in Crohn's disease.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Induction Chemotherapy; Mesalamine; Randomized Controlled Trials as Topic | 2015 |
Contemporary methods for the diagnosis and treatment of microscopic colitis.
Topics: Anti-Inflammatory Agents; Antidiarrheals; Bismuth; Budesonide; Colitis, Microscopic; Humans; Immunosuppressive Agents; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Organometallic Compounds; Probiotics; Risk Factors; Salicylates; Tumor Necrosis Factor-alpha | 2016 |
Oral budesonide for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Induction Chemotherapy; Mesalamine; Prednisone; Randomized Controlled Trials as Topic | 2015 |
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
Topics: Anti-Inflammatory Agents; Azathioprine; Budesonide; Colitis, Ulcerative; Congresses as Topic; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Maintenance Chemotherapy; Mesalamine; Methotrexate; Review Literature as Topic; Secondary Prevention | 2015 |
Budesonide for the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents; Biological Availability; Budesonide; Chemistry, Pharmaceutical; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Steroids; Treatment Outcome | 2016 |
Aminosalicylates for induction of remission or response in Crohn's disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Delayed-Action Preparations; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Randomized Controlled Trials as Topic; Sulfasalazine | 2016 |
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Medication Adherence; Mesalamine; Polymers; Remission Induction; Treatment Outcome | 2017 |
Diagnosis and Management of Microscopic Colitis.
Topics: Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Autoimmunity; Bile Acids and Salts; Budesonide; Cholestyramine Resin; Colitis, Collagenous; Colitis, Lymphocytic; Colitis, Microscopic; Collagen; Colon; Genetic Predisposition to Disease; Glucocorticoids; HLA Antigens; Humans; Mesalamine | 2017 |
[Second Korean Guidelines for the Management of Crohn's Disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Infliximab; Mercaptopurine; Mesalamine; Methotrexate; Prednisolone; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2017 |
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Bayes Theorem; Budesonide; Comparative Effectiveness Research; Crohn Disease; Humans; Induction Chemotherapy; Mesalamine; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Sulfasalazine; Treatment Outcome | 2017 |
Interventions for treating lymphocytic colitis.
Topics: Anti-Inflammatory Agents; Antidiarrheals; Beclomethasone; Bismuth; Budesonide; Cholestyramine Resin; Colitis, Lymphocytic; Humans; Mesalamine; Organometallic Compounds; Randomized Controlled Trials as Topic; Salicylates | 2017 |
Interventions for treating collagenous colitis.
Topics: Bismuth; Boswellia; Budesonide; Cholestyramine Resin; Chronic Disease; Colitis, Collagenous; Diarrhea; Glucocorticoids; Humans; Mesalamine; Organometallic Compounds; Plant Extracts; Prednisolone; Probiotics; Randomized Controlled Trials as Topic; Salicylates | 2017 |
A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Biological Availability; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Drug Delivery Systems; Humans; Mesalamine; Severity of Illness Index | 2018 |
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Network Meta-Analysis; Remission Induction; Sulfasalazine | 2018 |
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2019 |
Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antidiarrheals; Antimetabolites; Azathioprine; Biological Products; Budesonide; Colitis, Collagenous; Colitis, Lymphocytic; Colitis, Microscopic; Diarrhea; Humans; Loperamide; Malabsorption Syndromes; Mesalamine; Methotrexate; Prednisolone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time Factors | 2020 |
Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Immunological; Budesonide; Carcinoma, Signet Ring Cell; Crohn Disease; Drug Therapy, Combination; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Mesalamine; Middle Aged; Neoplasms, Multiple Primary; Rituximab; Stomach Neoplasms; Treatment Outcome | 2020 |
Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.
Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Retrospective Studies; Technology | 2021 |
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review.
Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine | 2022 |
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Proctitis; Remission Induction; Tacrolimus | 2023 |
17 trial(s) available for mesalamine and pulmicort
| Article | Year |
|---|---|
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Mesalamine; Middle Aged; Remission Induction | 1998 |
Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
Topics: Administration, Topical; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic | 1999 |
[Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Aged; Pilot Projects; Proctoscopy; Prospective Studies; Treatment Outcome | 2000 |
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Double-Blind Method; Female; Health Status; Humans; Male; Mesalamine; Middle Aged; Quality of Life; Severity of Illness Index | 2002 |
Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Female; Humans; Male; Mesalamine; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Single-Blind Method; Treatment Outcome | 2003 |
Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Aged; Quality of Life; Treatment Outcome; Young Adult | 2010 |
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Crohn Disease; Double-Blind Method; Female; Humans; Male; Mesalamine; Middle Aged; Remission Induction; Severity of Illness Index; Smoking; Treatment Outcome; Young Adult | 2011 |
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Chi-Square Distribution; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Mesalamine; Middle Aged; Remission Induction | 2011 |
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Mesalamine; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2012 |
Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Capsules; Colitis, Collagenous; Defecation; Delayed-Action Preparations; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2014 |
Smoking Status Influences Clinical Outcome in Collagenous Colitis.
Topics: Aged; Budesonide; Colitis, Collagenous; Colon; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Prognosis; Remission Induction; Smoking; Treatment Outcome | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colon, Sigmoid; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Proctitis; Proctocolitis; Remission Induction; Severity of Illness Index | 2016 |
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colonoscopy; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hydrocortisone; Intention to Treat Analysis; Male; Mesalamine; Middle Aged; Remission Induction; Retreatment; Severity of Illness Index | 2017 |
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Male; Mesalamine; Middle Aged; Proctitis; Prospective Studies; Russia; Suppositories; Treatment Outcome; Young Adult | 2019 |
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Budesonide; Colitis, Lymphocytic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Male; Mesalamine; Middle Aged; Treatment Outcome | 2018 |
Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colon; Colonoscopy; Delayed-Action Preparations; Drug Administration Schedule; Drug Resistance; Female; Humans; Intestinal Mucosa; Male; Mesalamine; Middle Aged; Proof of Concept Study; Remission Induction; Treatment Outcome; Young Adult | 2020 |
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Topics: Budesonide; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Proctitis; Quality of Life; Remission Induction; Treatment Outcome | 2022 |
57 other study(ies) available for mesalamine and pulmicort
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid.
Topics: Animals; Budesonide; Colitis; Colon; Cyclosporine; Disease Models, Animal; Female; Intestinal Mucosa; Mesalamine; Organ Size; Oxazolone; Peroxidase; Rats; Time Factors | 1998 |
Treatment of Crohn's disease at the turn of the century.
Topics: Administration, Topical; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Tumor Necrosis Factor-alpha | 1998 |
A comparison of budesonide and mesalamine for active Crohn's disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Immunosuppressive Agents; Mesalamine; Multicenter Studies as Topic; Prednisolone; Remission Induction | 1999 |
[Extra-intestinal manifestations and complications in chronic active ulcerative colitis in childhood and adolescence].
Topics: Adolescent; Azathioprine; Budesonide; Child; Colitis, Ulcerative; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Leg Ulcer; Male; Mesalamine; Prednisolone; Pyoderma Gangrenosum; Treatment Outcome | 1999 |
Beneficial effects of ropivacaine in rat experimental colitis.
Topics: Acetylcholine; Amides; Anesthetics, Local; Animals; Budesonide; Colitis; Ethanol; Gastrointestinal Motility; In Vitro Techniques; Male; Mesalamine; Mucous Membrane; Peroxidase; Rats; Rats, Sprague-Dawley; Ropivacaine; Time Factors; Trinitrobenzenesulfonic Acid; Wound Healing | 1999 |
Drug Points: Anaphylactic-like reaction associated with oral budesonide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Mesalamine | 2000 |
[Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].
Topics: Adult; Ambulatory Care; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Cost of Illness; Costs and Cost Analysis; Crohn Disease; Drug Costs; Germany; Health Care Costs; Health Resources; Hospitals, University; Humans; Mesalamine | 2002 |
Ileal Crohn's disease is best treated by surgery.
Topics: Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Humans; Ileum; Mesalamine; Prednisolone | 2002 |
[Treatment of steroid-refractory ulcerative colitis with infliximab].
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Blood Transfusion; Budesonide; Colitis, Ulcerative; Drug Resistance; Drug Therapy, Combination; Enteral Nutrition; Female; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methylprednisolone; Prednisone; Remission Induction; Tumor Necrosis Factor-alpha | 2003 |
[Acute episode].
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Child; Controlled Clinical Trials as Topic; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Mercaptopurine; Mesalamine; Meta-Analysis as Topic; Nutritional Physiological Phenomena; Prednisolone; Time Factors | 2003 |
[Maintaining a remission].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Child; Crohn Disease; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Male; Mercaptopurine; Mesalamine; Meta-Analysis as Topic; Methotrexate; Placebos; Postoperative Care; Prednisolone; Pregnancy; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Time Factors | 2003 |
Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up.
Topics: Aged; Budesonide; Cholestyramine Resin; Colitis; Collagen; Colon; Female; Follow-Up Studies; Humans; Lymphocytosis; Male; Mesalamine; Middle Aged; Prednisone; Prospective Studies; Time Factors | 2003 |
[New research results give hope. Causal therapy of Crohn disease in sight].
Topics: Algorithms; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Defensins; Humans; Immunosuppressive Agents; Mesalamine; Prednisolone; Prognosis; Time Factors; Trichuris | 2004 |
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Quality of Life; Sulfasalazine; Time Factors | 2005 |
Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
Topics: Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Delivery Systems; Gastrointestinal Transit; Hydrogen-Ion Concentration; Kinetics; Mesalamine; Models, Biological; Solubility; Spectrophotometry, Ultraviolet | 2005 |
[Paradigmatic shift in drug treatment of Crohn disease].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Immunosuppressive Agents; Mesalamine; Prednisolone; Secondary Prevention | 2005 |
[Crohn disease, exacerbated during pregnancy].
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Crohn Disease; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Intestine, Small; Mesalamine; Pregnancy; Pregnancy Complications; Ultrasonography | 2007 |
Microscopic colitis: not just for aristocrats.
Topics: Budesonide; Cholestyramine Resin; Colitis, Microscopic; Humans; Immunosuppressive Agents; Incidence; Mesalamine; Risk Factors | 2007 |
[Patients prefer foam].
Topics: Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Humans; Mesalamine; Patient Acceptance of Health Care; Treatment Outcome | 2007 |
[Collagenous colitis. Clinicopathological study of 18 cases].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; Colitis, Collagenous; Colon; Colonoscopy; Diarrhea; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome | 2007 |
Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile?
Topics: Adult; Aged; Azathioprine; Budesonide; Canada; Crohn Disease; Cross-Sectional Studies; Decision Support Techniques; Fees, Pharmaceutical; Female; Fish Oils; Focus Groups; Gastrointestinal Agents; Humans; Male; Mesalamine; Metronidazole; Middle Aged; Patient Satisfaction; Postoperative Care; Regression Analysis; Reproducibility of Results; Secondary Prevention | 2008 |
[Treating distal ulcerative colitis intrarectally. Foam instead of enema, low volume rather than high volume].
Topics: Administration, Rectal; Budesonide; Colitis, Ulcerative; Enema; Humans; Hydrocortisone; Mesalamine; Patient Acceptance of Health Care; Proctocolitis; Randomized Controlled Trials as Topic | 2008 |
Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Female; Humans; Ileitis; Incidence; Male; Mesalamine; Metronidazole; Middle Aged; Pouchitis; Proctocolectomy, Restorative; Prospective Studies; Retrospective Studies | 2009 |
[Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Practice Guidelines as Topic; Prednisolone; Remission Induction | 2010 |
Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Topics: Administration, Oral; Anhydrides; Animals; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Colon; Dextrans; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Glutarates; Hydrogen-Ion Concentration; Male; Mesalamine; Molecular Weight; Rats; Rats, Wistar | 2011 |
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; Combined Modality Therapy; Crohn Disease; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Male; Mercaptopurine; Mesalamine; Methyltransferases; Monosomy; Myelodysplastic Syndromes; Prednisone; Young Adult | 2010 |
Small intestinal release mesalamine for the treatment of refractory celiac disease type I.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Celiac Disease; Female; Glucocorticoids; Headache; Humans; Intestine, Small; Male; Mesalamine; Middle Aged; Treatment Outcome | 2011 |
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Cyclosporine; Female; Germany; Humans; Immunosuppressive Agents; Infliximab; Male; Mercaptopurine; Mesalamine; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Remission Induction; Severity of Illness Index; Sex Factors; Tacrolimus | 2011 |
Budesonide use in pediatric Crohn disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Budesonide; Child; Colon; Colonic Diseases; Crohn Disease; Drug Therapy, Combination; Female; Humans; Ileal Diseases; Ileum; Immunologic Factors; Male; Mesalamine; Prednisone; Young Adult | 2012 |
[Guidelines for the management of Crohn's disease].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Budesonide; Crohn Disease; Databases, Factual; Female; Fistula; Humans; Infliximab; Intestinal Perforation; Male; Mercaptopurine; Mesalamine; Methotrexate; Prednisolone; Pregnancy; Recurrence; Risk Factors; Severity of Illness Index; Sulfasalazine | 2012 |
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Azathioprine; Budesonide; Cells, Cultured; Crohn Disease; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Interferon-gamma; Interleukin-10; Male; Mesalamine; Middle Aged; Retrospective Studies; T-Lymphocytes; Tumor Necrosis Factor-alpha; Young Adult | 2013 |
Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Colon; Cyclosporine; Dextran Sulfate; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Mesalamine; Mice; Mice, Inbred BALB C; Receptors, Prostaglandin E, EP4 Subtype; Thioguanine | 2013 |
Topical therapy is underused in patients with ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Immunologic Factors; Male; Mesalamine; Middle Aged; Proctitis; Severity of Illness Index; Switzerland; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Bacterial; Antibodies, Monoclonal; Azathioprine; Bacterial Proteins; Budesonide; Case-Control Studies; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infliximab; Male; Mesalamine; Middle Aged; Mycobacterium avium subsp. paratuberculosis; Prednisone; Protein Tyrosine Phosphatases; Young Adult | 2014 |
Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146(5):1222-1230 e1222.
Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Collagenous; Female; Gastrointestinal Agents; Humans; Male; Mesalamine | 2014 |
[Chronic inflammatory bowel diseases. Strive for healing the mucosa, prevent overtreatment].
Topics: Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Intestinal Mucosa; Mesalamine; Phosphatidylcholines | 2014 |
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Topics: Adolescent; Adult; Aged; Budesonide; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Colonoscopy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Socioeconomic Factors; Young Adult | 2015 |
[The first oral budesonide: effective in an acute episode].
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Budesonide; Colitis, Ulcerative; Drug Approval; Drug Therapy, Combination; Germany; Humans; Medication Adherence; Mesalamine | 2015 |
[Not a cure, but a normal life].
Topics: Azathioprine; Biological Products; Budesonide; Cell Adhesion Molecules; Drug Therapy, Combination; Humans; Inflammatory Bowel Diseases; Mesalamine; Tumor Necrosis Factor-alpha | 2016 |
Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
Topics: Budesonide; Delayed-Action Preparations; Humans; Inflammatory Bowel Diseases; Mesalamine; Tablets | 2016 |
Collagenous colitis and Crohn's disease: Guilty or innocent bystander?
Topics: Aged; Budesonide; Colitis, Collagenous; Colon; Colonoscopy; Crohn Disease; Humans; Male; Mesalamine; Recurrence | 2016 |
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Drug Delivery Systems; Drug Therapy, Combination; Glucocorticoids; Humans; Mesalamine; Risk Assessment | 2017 |
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Remission Induction | 2017 |
Rosacea fulminans - coincidence of the disease with inflammatory bowel disease.
Topics: Anti-Inflammatory Agents; Budesonide; Dermatologic Agents; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Middle Aged; Rosacea | 2019 |
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplasms; Disease Management; Early Detection of Cancer; Gastroenterology; Gastrointestinal Agents; Humans; Infliximab; Maintenance Chemotherapy; Mesalamine; Prognosis; Remission Induction; Severity of Illness Index; Societies, Medical; Tumor Necrosis Factor-alpha | 2019 |
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Azathioprine; Budesonide; Canada; Crohn Disease; Gastroenterology; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Methotrexate; Prednisolone; Societies, Medical; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Colonoscopy; Female; Humans; Mesalamine; Methylprednisolone; Pneumonia; Probiotics; Pulmonary Eosinophilia; Recurrence; Thorax; Tomography, X-Ray Computed | 2019 |
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Logistic Models; Male; Mesalamine; Middle Aged; Multivariate Analysis; Retrospective Studies; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2019 |
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Cohort Studies; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2019 |
Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
Topics: Aged; Budesonide; Colonic Diseases; Diverticular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Feces; Female; Follow-Up Studies; Gastrointestinal Agents; Glucocorticoids; Humans; Leukocyte L1 Antigen Complex; Male; Mesalamine; Middle Aged; Severity of Illness Index; Treatment Outcome | 2019 |
A new kid on the budesonide block.
Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine | 2020 |
Panuveitis in a patient with active Crohn's disease.
Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colonoscopy; Crohn Disease; Female; Humans; Mesalamine; Panuveitis; Tomography, Optical Coherence | 2021 |
Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study.
Topics: Budesonide; Colitis, Ulcerative; Defecation; Humans; Mesalamine; Quality of Life; Treatment Outcome | 2022 |